干扰素信号细胞自主性失调驱动SRSF2突变型MDS干/祖细胞克隆扩增
研究利用人同基因诱导多能干细胞模型及MDS患者原代细胞,发现SRSF2 P95L突变下调STAT1基础表达,削弱干扰素信号,使MDS干/祖细胞对干扰素抑制克隆形成的能力产生抵抗;蛋白酶体抑制剂硼替佐米可升高STAT1蛋白水平并恢复突变细胞对炎症刺激的敏感性,提示蛋白酶体抑制可能是治疗SRSF2突变MDS的潜在策略。
要点
- SRSF2 P95L突变下调STAT1基础表达,削弱MDS干/祖细胞干扰素信号。
- SRSF2突变细胞对干扰素抑制克隆形成的能力产生抵抗,正常HSPC无此表现。
- 硼替佐米升高STAT1蛋白水平并恢复SRSF2突变细胞对炎症刺激的敏感性。
核心结论
- SRSF2突变通过重塑STAT1信号削弱对干扰素的反应性,在炎症刺激存在下赋予SRSF2突变HSPC相对于正常HSPC的克隆适应优势。
- 研究提示蛋白酶体抑制可能是治疗SRSF2突变MDS的潜在策略。
研究设计与样本
- 研究采用人同基因诱导多能干细胞来源的SRSF2突变MDS模型及MDS患者原代细胞。
主要发现
- SRSF2 P95L突变下调STAT1基础表达。
- STAT1下调削弱MDS干/祖细胞中的干扰素信号,与正常HSPC不同,MDS干/祖细胞对干扰素抑制克隆形成的能力表现出抵抗。
- 硼替佐米处理升高STAT1蛋白水平并恢复SRSF2突变细胞对炎症刺激的敏感性。
临床怎么用
- 作者提出蛋白酶体抑制可能是治疗SRSF2突变MDS的潜在策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myelodysplastic syndromes (MDSs) are myeloid malignancies often driven by mutations in genes encoding splicing factors (SFs). How these mutations drive the clonal expansion of MDS stem/progenitor cells to outcompete normal hematopoietic stem/progenitor cells (HSPCs) remains unexplained. Although a role for inflammatory processes in promoting clonal expansion of mutant HSPCs and MDS pathogenesis has been proposed, the specific mechanisms implicated remain incompletely understood. In this study, using human isogenic induced pluripotent stem cell-based models of SRSF2-mutant MDS and primary cells from patients with MDS, we show that the SRSF2 P95L mutation downregulates basal STAT1 expression. STAT1 downregulation dampens interferon (IFN) signaling in MDS stem/progenitor cells, which, unlike normal HSPCs, show resistance to the suppression of clonogenic ability by IFNs. Treatment with the proteasome inhibitor bortezomib increased STAT1 protein levels and restored the sensitivity of SRSF2-mutant cells to inflammatory stimuli. These results indicate that rewiring of STAT1 signaling by SRSF2 mutations blunts responsiveness to IFNs, conferring clonal fitness to SRSF2-mutant HSPCs against normal HSPCs in the presence of inflammatory stimuli. Our study provides a novel mechanistic link between SF mutations and inflammatory dysregulation and suggests proteasome inhibition as a potential strategy to treat MDS with SRSF2 mutations.
引用
- Takashima K, Olszewska M, Jethalia V, et al. Cell-autonomous dysregulation of interferon signaling drives clonal expansion of SRSF2-mutant MDS stem/progenitor cells. Blood. 2025. PMID: 40163808. doi:10.1182/blood.2024025670
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。